Welcome to the BRACE trial
This Australian-led study is the world’s largest trial on the off-target effects of Bacille Calmette-Guérin (BCG) vaccine. More than 6800 healthcare workers have been enrolled in Australia, Brazil, Spain, the Netherlands and the United Kingdom.
In addition to preventing severe tuberculosis (TB) in children, BCG vaccine has off-target (non-specific or immunomodulatory) effects. That’s why this multi-centre, randomised controlled clinical trial is working to determine:
Recruitment to the BRACE trial has now closed
The first healthcare workers were enrolled at the Royal Children’s Hospital, Melbourne, Australia in March 2020, and the final participants in Manaus, Brazil in March 2021.
The BRACE trial goes global
Hear from Professor Nigel Curtis, Chief Principal Investigator of the BRACE trial, as he discusses whether BCG vaccine might protect healthcare workers against COVID-19.
Introducing the BRACE COVID-19-Specific vaccine sub-study (BCOS)
The BRACE trial has introduced a sub-study at selected sites in Australia and Brazil to investigate whether it’s possible to predict who remains susceptible to SARS-CoV-2 variants despite previous COVID-19 disease or COVID-19-specific vaccination. The sub-study will look at whether BCG vaccine, by boosting the immune system, improves the response to Pfizer, AstraZeneca and CoronaVac vaccines.
MCRI’s BCG vaccine trial joins global race to better understand COVID-19 variants
Could BCG vaccine protect against COVID-19? UK recruitment begins
$10M grant enables MCRI’s BCG vaccine trial to expand internationally
MCRI to trial preventative vaccine for COVID-19 healthcare workers